Celecoxib enhances the anti-Inflammatory effects of farnesylthiosalicylic acid on T cells independent of prostaglandin E2 production

Inflammation

Volumn 35, Issue 5, 2012, Pages 1706-1714

  Mor, Adam ^a,b   Aizman, Elizabeta ^b   Kloog, Yoel ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Celecoxib; FTS; Ras; T cells

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; SALIRASIB;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL ADHESION; CYTOKINE RELEASE; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; GENE ACTIVATION; GENE REPRESSION; HUMAN; HUMAN CELL; INFLAMMATORY DISEASE; LYMPHOCYTE; MOUSE; NONHUMAN; ONCOGENE RAS; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; T LYMPHOCYTE;

ANIMALS; CELL ADHESION; CELL LINE; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FARNESOL; HUMANS; INTERLEUKIN-2; JURKAT CELLS; MICE; MICE, INBRED BALB C; ONCOGENE PROTEIN P21(RAS); PHOSPHORYLATION; PYRAZOLES; SALICYLATES; SULFONAMIDES; T-LYMPHOCYTES;

EID: 84866735583     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-012-9488-8     Document Type: Article

References (22)

1. Burmester, G., A. Lanas, L. Biasucci, M. Hermann, S. Lohmander, I. Olivieri, et al. 2011. The appropriate use of non-steroidal antiinflammatory drugs in rheumatic disease: Opinions of amultidisciplinary European expert panel. Annals of the Rheumatic Diseases 70: 818-822.
2. Arber, N., C.J. Eagle, J. Spicak, I. Rácz, P. Dite, J. Hajer, et al. 2006. Celecoxib for the prevention of colorectal adenomatous polyps. The New England Journal of Medicine 355: 885-895.
3. Mor, A., R. Haklai, O. Ben-Moshe, Y.A. Mekori, and Y. Kloog. 2011. Inhibition of contact sensitivity by farnesylthiosalicylic acidamide, a potential Rap1 inhibitor. The Journal of Investigative Dermatology 131: 2040-2048.
4. Aizman, E., A. Mor, J. Chapman, Y. Assaf, and Y. Kloog. 2010. The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice. Journal of Neuroimmunology 229: 192-203.
5. Mor, A., O. Ben-Moshe, Y.A. Mekori, and Y. Kloog. 2011. Inhibitory effect of farnesylthiosalicylic acid on mediators release by mast cells: Preferential inhibition of prostaglandin D2 and tumor necrosis factor-α release. Inflammation 34: 314-318.
6. Hoang, B., L. Zhu, Y. Shi, P. Frost, H. Yan, S. Sharma, et al. 2006. Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. Blood 107: 4484-4490.
7. Capodici, C., M.H. Pillinger, G. Han, M.R. Philips, and G. Weissmann. 1998. Integrin-dependent homotypic adhesion of neutrophils. Arachidonic acid activates Raf-1/Mek/Erk via a 5-lipoxygenase-dependent pathway. The Journal of Clinical Investigation 102: 165-175.
8. Mor, A., M.L. Dustin, and M.R. Philips. 2007. Small GTPases and LFA-1 reciprocally modulate adhesion and signaling. Immunological Reviews 218: 114-125.
9. Mor, A., G. Campi, G. Du, Y. Zheng, D.A. Foster, M.L. Dustin, et al. 2007. The lymphocyte function-associated antigen-1 receptor costimulates plasma membrane Ras via phospholipase D2. Nature Cell Biology 9: 713-719.
10. Chou, T.C. 2010. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Research 70: 440-446.
11. Patel, M.I., K. Subbaramaiah, B. Du, M. Chang, P. Yang, R.A. Newman, et al. 2005. Celecoxib inhibits prostate cancer growth: Evidence of a cyclooxygenase-2-independent mechanism. Clinical Cancer Research 11: 1999-2007.
12. Du, J., B. Jiang, and J. Barnard. 2005. Differential regulation of cyclooxygenase-2 in nontransformed and ras-transformed intestinal epithelial cells. Neoplasia 7: 761-770.
13. Repasky, G.A., Y. Zhou, S. Morita, and C.J. Der. 2007. Rasmediated intestinal epithelial cell transformation requires cyclooxygenase-2-induced prostaglandin E2 signaling. Molecular Carcinogenesis 46: 958-970.
14. Funahashi, H., M. Satake, D. Dawson, N.A. Huynh, H.A. Reber, O.J. Hines, et al. 2007. Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Research 67: 7068-7071.
15. Pillinger, M.H., C. Capodici, P. Rosenthal, N. Kheterpal, S. Hanft, M.R. Philips, et al. 1998. Modes of action of aspirin-like drugs: Salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. Proceedings of the National Academy of Sciences of the United States of America 95: 14540-14545.
16. Wang, D., F.G. Buchanan, H. Wang, S.K. Dey, and R.N. DuBois. 2005. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Research 65: 1822-1829.
17. Dajani, O.F., K.Meisdalen, T.K. Guren,M. Aasrum, I.H. Tveteraas, P. Lilleby, et al. 2008. Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes. Journal of Cellular Physiology 214: 371-380.
18. Grösch, S., I. Tegeder, E. Niederberger, L. Bräutigam, and G. Geisslinger. 2001. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. The FASEB Journal 15: 2742-2744.
19. Jendrossek, V., R. Handrick, and C. Belka. 2003. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. The FASEB Journal 17: 1547-1549.
20. Brueggemann, L.I., A.R. Mackie, B.K. Mani, L.L. Cribbs, and K.L. Byron. 2009. Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles. Molecular Pharmacology 76: 1053-1061.
21. Iñiguez, M.A., C. Punzón, and M. Fresno. 1999. Induction of cyclooxygenase-2 on activated T lymphocytes: Regulation of T cell activation by cyclooxygenase-2 inhibitors. Journal of Immunology 163: 111-119.
22. Iñiguez, M.A., C. Punzón, C. Cacheiro-Llaguno, M.D. Díaz-Muñoz, J. Duque, R. Cuberes, et al. 2010. Cyclooxygenaseindependent inhibitory effects on T cell activation of novel 4,5-dihydro-3 trifluoromethyl pyrazole cyclooxygenase-2 inhibitors. International Immunopharmacology 10: 1295-1304.